GUD Stock Overview Develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. More details
Rewards Risk Analysis No risks detected for GUD from our risk checks.
See All Risk Checks Capture your thoughts, links and company narrative
Knight Therapeutics Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Knight Therapeutics Historical stock prices Current Share Price CA$5.19 52 Week High CA$6.23 52 Week Low CA$5.09 Beta 0.49 1 Month Change -0.38% 3 Month Change -13.79% 1 Year Change -0.38% 3 Year Change -0.95% 5 Year Change -31.80% Change since IPO 35.51%
Recent News & Updates
Knight Therapeutics Inc. Announces Filing of New Drug Submission for Qelbree® (Viloxazine) in Canada Dec 17
Knight Therapeutics Announces Regulatory Approval of TAVALISSE® in Mexico Dec 13
Knight Therapeutics Inc. Announces Health Canada Approval for JORNAY PM™ to Treat Attention-Deficit Hyperactivity Disorder Nov 15
President recently bought CA$103k worth of stock Nov 12
Knight Therapeutics Inc. (TSE:GUD) Just Reported Earnings, And Analysts Cut Their Target Price Nov 09
New major risk - Revenue and earnings growth Nov 08 See more updates
Knight Therapeutics Inc. Announces Filing of New Drug Submission for Qelbree® (Viloxazine) in Canada Dec 17
Knight Therapeutics Announces Regulatory Approval of TAVALISSE® in Mexico Dec 13
Knight Therapeutics Inc. Announces Health Canada Approval for JORNAY PM™ to Treat Attention-Deficit Hyperactivity Disorder Nov 15
President recently bought CA$103k worth of stock Nov 12
Knight Therapeutics Inc. (TSE:GUD) Just Reported Earnings, And Analysts Cut Their Target Price Nov 09
New major risk - Revenue and earnings growth Nov 08
Third quarter 2024 earnings released: EPS: CA$0.001 (vs CA$0.09 in 3Q 2023) Nov 08
Knight Therapeutics Inc. to Report Q3, 2024 Results on Nov 07, 2024 Oct 31
Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind Aug 09
Knight Therapeutics Inc. Revises Earnings Guidance for the Year 2024 Aug 09
Knight Therapeutics Inc. to Report Q2, 2024 Results on Aug 08, 2024 Aug 01
Independent Director recently sold CA$148k worth of stock May 30
Executive Chairman exercised options to buy CA$543k worth of stock. May 23
Price target increased by 7.3% to CA$7.24 May 13
Knight Therapeutics Inc. Reconfirms Earnings Guidance for the Year 2024 May 10
First quarter 2024 earnings released: CA$0.045 loss per share (vs CA$0.035 loss in 1Q 2023) May 09
Knight Therapeutics Inc. to Report Q1, 2024 Results on May 09, 2024 May 03
President exercised options to buy CA$309k worth of stock. Apr 10
Full year 2023 earnings released: CA$0.16 loss per share (vs CA$0.26 loss in FY 2022) Mar 22
Knight Therapeutics Inc. to Report Q4, 2023 Results on Mar 21, 2024 Mar 15
Knight Therapeutics Inc., Annual General Meeting, May 08, 2024 Feb 24
Knight Therapeutics Inc. Announces Regulatory Submission of Fostamatinib in Brazil Feb 23
Knight Therapeutics Inc. Announces Launch of Bijuva® in Canada Feb 06
New major risk - Revenue and earnings growth Nov 11
Third quarter 2023 earnings: EPS and revenues exceed analyst expectations Nov 11
Knight Therapeutics Inc. to Report Q3, 2023 Results on Nov 09, 2023 Nov 03
Knight Therapeutics Inc. Announces CMED Price Approval of Minjuvi (tafasitamab) in Brazil Oct 17
United Medical Ltd. Announces Regulatory Submission of Pemigatinib in Brazil Oct 11
Executive Chairman recently bought CA$111k worth of stock Sep 28
Knight Therapeutics Inc. Updates Earnings Guidance for the Fiscal Year 2023 Aug 11
Second quarter 2023 earnings: EPS and revenues exceed analyst expectations Aug 10 Knight Therapeutics Inc. to Report Q2, 2023 Results on Aug 10, 2023 Aug 04
Insufficient new directors Jul 01
President recently bought CA$95k worth of stock May 26
Knight Therapeutics Inc. Updates Revenue Guidance for the Fiscal 2023 May 13
First quarter 2023 earnings released: CA$0.035 loss per share (vs CA$0.16 loss in 1Q 2022) May 11
Knight Therapeutics Inc. to Report Q1, 2023 Results on May 11, 2023 May 05
Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind Mar 31
Consensus EPS estimates fall by 309% Mar 26
Price target decreased by 12% to CA$6.30 Mar 24
Knight Therapeutics Inc. Announces Relaunch of AKYNZEO in Canada Dec 02
Third quarter 2022 earnings: EPS and revenues exceed analyst expectations Nov 16
Third quarter 2022 earnings: EPS and revenues exceed analyst expectations Nov 11 Knight Therapeutics Inc. Reports Impairment of Intangible Assets for the Third Quarter Ended September 30, 2022
Knight Therapeutics Inc. to Report Q3, 2022 Results on Nov 10, 2022 Nov 04
Knight Therapeutics Announces Regulatory Submission for Tafasitamab in Brazil Oct 07
Second quarter 2022 earnings: EPS and revenues exceed analyst expectations Aug 12
Knight Therapeutics Inc. to Report Q2, 2022 Results on Aug 11, 2022 Aug 05
Executive Chairman recently bought CA$135k worth of stock Jul 09
Executive Chairman recently bought CA$104k worth of stock Jun 18
Executive Chairman recently bought CA$207k worth of stock May 20
Consensus forecasts updated May 19
First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind May 13
Knight Therapeutics Inc. Provides Revenue Guidance for the Fiscal Year 2022 May 13
Knight Therapeutics Inc. to Report Q1, 2022 Results on May 12, 2022 May 06
Price target decreased to CA$6.86 Apr 27
Independent Director recently bought CA$89k worth of stock Apr 15
President recently bought CA$104k worth of stock Apr 02
Full year 2021 earnings: EPS and revenues miss analyst expectations Mar 29
Knight Therapeutics Inc., Annual General Meeting, May 11, 2022 Feb 26
Knight Therapeutics Inc. Announces Approval of Halaven® in Colombia Jan 07
Executive Chairman recently bought CA$102k worth of stock Jan 07
Executive Chairman recently bought CA$102k worth of stock Jan 07
Knight Therapeutics Inc. Announces Approval of Lenvima® in Colombia Jan 06
President recently bought CA$82k worth of stock Dec 15
Executive Chairman recently bought CA$105k worth of stock Dec 08
Executive Chairman recently bought CA$95k worth of stock Nov 17
Third quarter 2021 earnings released: CA$0.07 loss per share (vs CA$0.14 profit in 3Q 2020) Nov 12
High number of new directors Nov 02
High number of new directors Oct 02
Executive Chairman recently bought CA$105k worth of stock Sep 22
CEO & Director recently bought CA$202k worth of stock Aug 20
Consensus EPS estimates increase to CA$0.28 Aug 20
Second quarter 2021 earnings released: EPS CA$0.23 (vs CA$0.13 in 2Q 2020) Aug 14
CEO & Director recently bought CA$94k worth of stock Jul 05
CEO & Director recently bought CA$189k worth of stock May 29
Does Knight Therapeutics (TSE:GUD) Have A Healthy Balance Sheet? May 28
Knight Therapeutics Announces Closing of Previously Announce Acquisition and Exclusive License to Exelon® in Canada and Latin America May 27
Consensus forecasts updated May 21
First quarter 2021 earnings released: EPS CA$0.028 (vs CA$0.013 loss in 1Q 2020) May 16
Shareholders May Not Be So Generous With Knight Therapeutics Inc.'s (TSE:GUD) CEO Compensation And Here's Why May 07
Consensus EPS estimates increase to -CA$0.05 Apr 24
Calculating The Fair Value Of Knight Therapeutics Inc. (TSE:GUD) Apr 07
Consensus forecasts updated Apr 01
Full year 2020 earnings released: EPS CA$0.32 (vs CA$0.10 in FY 2019) Mar 27
Knight Therapeutics Inc. Reports Impairment Charges for the Fourth Quarter Ended December 31, 2020 Mar 27
Read This Before Selling Knight Therapeutics Inc. (TSE:GUD) Shares Mar 20
Knight Therapeutics Inc. to Report Q4, 2020 Results on Mar 25, 2021 Mar 19
If You Had Bought Knight Therapeutics' (TSE:GUD) Shares Three Years Ago You Would Be Down 34% Mar 02
New 90-day low: CA$5.16 Feb 27
Knight Therapeutics Inc., Annual General Meeting, May 13, 2021 Feb 26
Knight Therapeutics (TSE:GUD) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway Feb 03
Knight Therapeutics's (TSE:GUD) Earnings Are Growing But Is There More To The Story? Jan 19
Independent Director recently bought CA$105k worth of stock Jan 15
What Type Of Shareholders Own The Most Number of Knight Therapeutics Inc. (TSE:GUD) Shares? Jan 04
A Look At The Fair Value Of Knight Therapeutics Inc. (TSE:GUD) Dec 20
The Founder of Knight Therapeutics Inc. (TSE:GUD), Jonathan Goodman, Just Bought A Few More Shares Dec 07
Founder recently bought CA$118k worth of stock Dec 06 Shareholder Returns GUD CA Pharmaceuticals CA Market 7D -0.2% -1.2% -3.7% 1Y -0.4% -24.4% 15.0%
See full shareholder returns
Return vs Market: GUD underperformed the Canadian Market which returned 15% over the past year.
Price Volatility Is GUD's price volatile compared to industry and market? GUD volatility GUD Average Weekly Movement 4.2% Pharmaceuticals Industry Average Movement 12.0% Market Average Movement 8.2% 10% most volatile stocks in CA Market 17.6% 10% least volatile stocks in CA Market 2.9%
Stable Share Price: GUD has not had significant price volatility in the past 3 months compared to the Canadian market.
Volatility Over Time: GUD's weekly volatility (4%) has been stable over the past year.
About the Company Knight Therapeutics Inc. develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma. The company provides Ladecvina for multiple myeloma and myelodysplastic syndrome, mantle cell lymphoma, and follicular lymphoma; Zyvalix for metastatic prostate cancer; Karfib for relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; Rembre for chronic myeloid leukemia; Palbocil for breast cancer; Ambisome and Cresemba for fungal infection; Impavido for leishmaniasis; Dolufevir for HIV infection; Exelon for dementia; and Ibsrela for irritable bowel syndrome with constipation.
Show more Knight Therapeutics Inc. Fundamentals Summary How do Knight Therapeutics's earnings and revenue compare to its market cap? GUD fundamental statistics Market cap CA$520.14m Earnings (TTM ) -CA$30.73m Revenue (TTM ) CA$348.64m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) GUD income statement (TTM ) Revenue CA$348.64m Cost of Revenue CA$180.37m Gross Profit CA$168.27m Other Expenses CA$199.00m Earnings -CA$30.73m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -0.30 Gross Margin 48.26% Net Profit Margin -8.81% Debt/Equity Ratio 6.7%
How did GUD perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/20 22:29 End of Day Share Price 2024/12/20 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Knight Therapeutics Inc. is covered by 16 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution David Kideckel Beacon Securities Limited David Martin Bloom Burton & Co. Tania Armstrong-Whitworth Canaccord Genuity
Show 13 more analysts 
